EP Patent

EP0980258A1 — Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy

Assigned to Kennedy Trust for Rheumatology Research · Expires 2000-02-23 · 26y expired

What this patent protects

Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed are compositions comprising a TNFα antagonist and a VEGF antagonist. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune dise…

USPTO Abstract

Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed are compositions comprising a TNFα antagonist and a VEGF antagonist. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.

Drugs covered by this patent

Patent Metadata

Patent number
EP0980258A1
Jurisdiction
EP
Classification
—
Expires
2000-02-23
Drug substance claim
No
Drug product claim
No
Assignee
Kennedy Trust for Rheumatology Research
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.